Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:41:28.205Z.
Calculation as of: 2026-10-06T13:41:28.205Z.
Quote observation: 2026-10-06T13:40:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Market Cap
$1.47B
PE Ratio
12.53
TTM Avg
30.95
3Y Avg
30.73
5Y Avg
31.04
Market Cap
$1.52B
PE Ratio
144.52
TTM Avg
152.77
3Y Avg
83.75
5Y Avg
83.75
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.48B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 12.53 | 30.95 | 30.73 | 31.04 |
| GH Research PLC (GHRS)vs › | $1.51B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 9.01 | 9.41 | 9.41 | 62.32 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 144.52 | 152.77 | 83.75 | 83.75 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 5.05 | 13.44 | 25.81 | 17.64 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | 0.13 | 0.13 | 0.13 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.57B | N/A | 174.30 | 183.89 | 183.89 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.38B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
